Stomach Neoplasms
📧 Sign up to get email alerts when something new happens for Stomach Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-28EMA Authorised: Herzuma (trastuzumab) — Celltrion Healthcare Hungary Kft.
Authorised status for Herzuma (trastuzumab) in the European market for stomach and breast neoplasms.
-
EMA approval · 2026-08-18EMA Authorised: Herwenda (trastuzumab) — Sandoz GmbH
Authorised trastuzumab product Herwenda by Sandoz GmbH for breast and stomach neoplasms in the EU.
-
EMA approval · 2026-08-11EMA Authorised: Kanjinti (trastuzumab) — Amgen Europe B.V.
EMA authorises Kanjinti (trastuzumab) for indications including stomach and breast neoplasms.
-
EMA approval · 2026-07-08EMA Authorised: Trazimera (trastuzumab) — Pfizer Europe MA EEIG
Authorised status for Trazimera (trastuzumab) by Pfizer Europe MA EEIG in the EMA system for use in stomach and breast neoplasms.
-
EMA approval · 2026-04-28EMA Authorised: Dazublys (trastuzumab) — CuraTeQ Biologics s.r.o
Authorised monoclonal antibody therapy trastuzumab (Dazublys) for breast and stomach neoplasms in the EU.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
A clinical trial update describing a study on surgical approaches for Gastrointestinal Stromal Tumors, including tumor modeling and genomic …
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer [NA]
A clinical trial is recruiting to compare proximal versus total gastrectomy for locally advanced gastroesophageal junction cancer (Siewert T…
-
EMA approval · 2026-03-02EMA Authorised: Herceptin (trastuzumab) — Roche Registration GmbH
The EMA authorised Herceptin (trastuzumab) for stomach neoplasms and breast neoplasms. The marketing authorization holder is Roche Registrat…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Argon Plasma Coagulation Versus Endoscopic Mucosal Resection for Gastric Adenoma (CLER-GA) [NA]
This clinical trial is evaluating Argon Plasma Coagulation versus Endoscopic Mucosal Resection for gastric adenoma and is currently recruiti…
-
EMA approval · 2026-02-03EMA Authorised: Trazimera (trastuzumab) — Pfizer Europe MA EEIG
The EMA has authorised Trazimera (trastuzumab) for stomach and breast neoplasms, with Pfizer Europe MA EEIG as the marketing authorization h…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating lenvatinib in combination with nivolumab and chemotherapy for metastatic gastric cancer with malignant…
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer [Phase 2]
A Phase 2 clinical trial investigating conversion therapy plus surgery and radiotherapy for gastric cancer with retroperitoneal nodal metast…
-
CLINICAL_TRIALS trial_result · 2025-08-14Clinical Trial Update: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) [Phase 2]
Merck completed a Phase 2 trial (MK-7684A-005) evaluating MK-7684A with or without other anticancer therapies in selected solid tumors.
-
EMA approval · 2025-07-11EMA Authorised: Capecitabine Teva (capecitabine) — Teva Pharma B.V.
EMA authorised Capecitabine Teva (capecitabine), a generic capecitabine product by Teva Pharma B.V., for multiple cancer indications, includ…
-
CLINICAL_TRIALS research · 2025-01-20Clinical Trial Update: To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer [Phase 2, Phase 3]
Update on a Phase 2/Phase 3 clinical trial evaluating IAH0968 in combination with CAPEOX for HER2-positive gastric cancer; the study is curr…
-
CLINICAL_TRIALS research · 2024-11-07Clinical Trial Update: Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) [Phase 2]
Phase II trial evaluating the addition of Avelumab to chemotherapy as perioperative treatment for patients with resectable gastric cancer or…
-
CLINICAL_TRIALS trial_result · 2024-06-25Clinical Trial Update: An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy [NA]
Results from a study evaluating the ExSpiron Respiratory Variation Monitor during upper GI endoscopy have been posted.
-
CLINICAL_TRIALS trial_result · 2024-02-07Clinical Trial Update: The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer [Phase 2]
A Phase 2 clinical trial evaluating chemotherapy plus camrelizumab as conversion therapy in metastatic gastric cancer has completed.
-
CLINICAL_TRIALS trial_result · 2023-09-29Clinical Trial Update: Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients [Phase 3]
Phase 3 clinical trial comparing SEEOX and SOX regimens in stage IIIb/IIIc gastric cancer; status currently unknown.
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study [Phase 2]
Phase II, single-arm trial evaluating SOX regimen plus camrelizumab as neoadjuvant therapy for locally advanced gastric cancer; study status…
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis [Phase 3]
Phase 3 trial comparing intra-peritoneal catumaxomab infusion to investigator's treatment of choice in advanced gastric cancer with peritone…
-
EMA withdrawal · 2022-12-13EMA Application withdrawn: Tuznue (trastuzumab) — Prestige Biopharma Belgium
The EMA has withdrawn the application for Tuznue (trastuzumab) by Prestige Biopharma Belgium.
-
EMA withdrawal · 2022-12-13EMA Application withdrawn: Hervelous (trastuzumab) — Prestige Biopharma Belgium
The EMA indicates an application for Hervelous (trastuzumab) by Prestige Biopharma Belgium has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2022-10-19Clinical Trial Update: Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating the safety and efficacy of Esperanza Extract (PA001) for various neoplastic conditions; current status i…
-
CLINICAL_TRIALS trial_result · 2022-06-15Clinical Trial Update: Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer [Phase 2]
Phase 2 exploratory study evaluating Drug Sensitivity Prediction Software (IRCR-DReSS) using patient-derived tumor cells from metastatic gas…